These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 29397323)

  • 1. Combination therapy with cytapheresis plus vedolizumab in a corticosteroid-dependent patient with ulcerative colitis and previous ANTI-TNF-α drug failure.
    Sáez-González E; Aguas M; Huguet JM; Nos P; Beltrán B
    Dig Liver Dis; 2018 Apr; 50(4):415-417. PubMed ID: 29397323
    [No Abstract]   [Full Text] [Related]  

  • 2. Response to "The combination therapy with cytapheresis plus vedolizumab in a corticosteroid-dependent patient with ulcerative colitis and previous Anti-TNF alfa failure".
    Scrivo B; Vitello A; Cappello M
    Dig Liver Dis; 2018 Oct; 50(10):1103-1104. PubMed ID: 29871799
    [No Abstract]   [Full Text] [Related]  

  • 3. Should we use vedolizumab as mono or combo therapy in ulcerative colitis?
    Hedin C; Halfvarson J
    Best Pract Res Clin Gastroenterol; 2018; 32-33():27-34. PubMed ID: 30060935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recurrent COVID-19 in a Patient With Ulcerative Colitis on Vedolizumab Therapy.
    Crouwel F; Waaijenberg-Warmenhoven P; Buiter HJC; de Boer NK
    J Crohns Colitis; 2021 Jul; 15(7):1244-1245. PubMed ID: 33350449
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmacodynamic assessment of vedolizumab for the treatment of ulcerative colitis.
    McLean LP; Cross RK
    Expert Opin Drug Metab Toxicol; 2016 Jul; 12(7):833-42. PubMed ID: 27096357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists.
    Feagan BG; Rubin DT; Danese S; Vermeire S; Abhyankar B; Sankoh S; James A; Smyth M
    Clin Gastroenterol Hepatol; 2017 Feb; 15(2):229-239.e5. PubMed ID: 27639327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Current position on Vedolizumab for ulcerative colitis and Crohn's disease].
    Schreiber S; Dignass AU; Hartmann H; Kruis W; Rogler G; Siegmund B; Stallmach A; Witte C; Bokemeyer B
    Z Gastroenterol; 2015 Jun; 53(6):591-602. PubMed ID: 26016456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response to vedolizumab for children with steroid-refractory Ulcerative Colitis unresponsive to anti-TNF.
    Wiskin AE; Paul SP; Spray CH
    Acta Paediatr; 2019 Jul; 108(7):1359-1360. PubMed ID: 30788859
    [No Abstract]   [Full Text] [Related]  

  • 9. Vedolizumab for the treatment of ulcerative colitis.
    Stallmach A; Schmidt C; Teich N
    Expert Rev Gastroenterol Hepatol; 2016; 10(2):165-75. PubMed ID: 26588993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Using Vedolizumab to Treat Severe Sweet's Syndrome in a Patient With Ulcerative Colitis.
    Belvis Jiménez M; Maldonado Pérez B; Argüelles-Arias F
    J Crohns Colitis; 2018 Aug; 12(9):1134-1135. PubMed ID: 29788419
    [No Abstract]   [Full Text] [Related]  

  • 11. Successful Vedolizumab Therapy in a Sixteen-Year-Old Boy with Refractory Ulcerative Colitis.
    Zoet ID; de Boer NK; de Meij TG
    J Crohns Colitis; 2016 Mar; 10(3):373-4. PubMed ID: 26574489
    [No Abstract]   [Full Text] [Related]  

  • 12. A review of the cost-effectiveness of vedolizumab for treating moderate- to severely active ulcerative colitis.
    Tsai HH; Black C
    Expert Rev Pharmacoecon Outcomes Res; 2016 Dec; 16(6):679-683. PubMed ID: 27726457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Should we use anti-tumor necrosis factor agents or vedolizumab as first-line biological therapy in ulcerative colitis?
    Pouillon L; Van Stappen J; Bossuyt P; Danese S; Peyrin-Biroulet L
    Best Pract Res Clin Gastroenterol; 2018; 32-33():17-25. PubMed ID: 30060934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of vedolizumab in the treatment of ulcerative colitis.
    Domènech E; Gisbert JP
    Gastroenterol Hepatol; 2016 Dec; 39(10):677-686. PubMed ID: 26948838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of Vedolizumab in Patients with Antibiotic and Anti-tumor Necrosis Alpha Refractory Pouchitis.
    Philpott J; Ashburn J; Shen B
    Inflamm Bowel Dis; 2017 Jan; 23(1):E5-E6. PubMed ID: 27930413
    [No Abstract]   [Full Text] [Related]  

  • 16. Vedolizumab for ulcerative colitis and Crohn's disease: results and implications of GEMINI studies.
    Lam MC; Bressler B
    Immunotherapy; 2014; 6(9):963-71. PubMed ID: 25341118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vedolizumab use after failure of TNF-α antagonists in children and adolescents with inflammatory bowel disease.
    Schneider AM; Weghuber D; Hetzer B; Entenmann A; Müller T; Zimmermann G; Schütz S; Huber WD; Pichler J
    BMC Gastroenterol; 2018 Sep; 18(1):140. PubMed ID: 30219028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nodular vasculitis during treatment with vedolizumab in a patient with ulcerative colitis.
    Abbenante D; Merli Y; Misciali C; Sacchelli L; Bardazzi F
    Australas J Dermatol; 2022 Feb; 63(1):131-132. PubMed ID: 34817061
    [No Abstract]   [Full Text] [Related]  

  • 19. Co-treatment With Golimumab and Vedolizumab to Treat Severe UC and Associated Spondyloarthropathy.
    Roblin X; Paul S; Ben-Horin S
    J Crohns Colitis; 2018 Feb; 12(3):379-380. PubMed ID: 29088342
    [No Abstract]   [Full Text] [Related]  

  • 20. Cutaneous Vasculitis Associated With Vedolizumab in Ulcerative Colitis.
    de Freitas LF; Feitosa MR; Féres O; Parra RS
    Inflamm Bowel Dis; 2021 Jan; 27(2):e15-e17. PubMed ID: 33048114
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.